Track topics on Twitter Track topics that are important to you
Gene therapy developer Neurogene has appointed Stuart Cobb to serve as its chief scientific officer. Cobb is currently a scientist at the University of Edinburgh. Neurogene says he will split his time...
Neurogene is breaking into gene therapy with $68.5 million in new funding to support research on experimental treatments for rare, genetic brain disorders, the first of which could start human testing...
Neurogene said investors included Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund. The proceeds will support a product pipeli...
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended...Read More... The post Neurogene raises funds to support gene therap...
A round of Series A funding raised $68.5 million for Neurogene. -More-
Proceeds support a product pipeline with multiple AAV-based gene therapies with disease-modifying potential and creation of a company-owned AAV manufacturing facility ...
- Appointment bolsters Neurogene’s mission to bring life-changing therapies to patients with rare neurological disorders - Neurogene, Inc., a new company fo...
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advo...
We have published hundreds of Neurogene, Inc. news stories on BioPortfolio along with dozens of Neurogene, Inc. Clinical Trials and PubMed Articles about Neurogene, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurogene, Inc. Companies in our database. You can also find out about relevant Neurogene, Inc. Drugs and Medications on this site too.